NCT04757532View on ClinicalTrials.gov

Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 3, 2020

Primary Completion Date

March 10, 2021

Study Completion Date

March 10, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

Bupropion

300 mg of bupropion hydrochloride (1 tablet) administered orally in a single dose.

DRUG

Anastrozole

1 mg of anastrozole (1 tablet) administered orally in a single dose.

DRUG

Testosterone cyclopentylpropionate

100 mg of testosterone cyclopentylpropionate (equivalent to 70 mg of testosterone) administered via intramuscular injection in a single dose (2 mL).

DRUG

Danazol

200 mg of danazol (1 capsule) administered orally in a single dose.

DRUG

Chlorthalidone

50 mg of chlorthalidone (1 tablet) administered orally in a single dose.

Trial Locations (1)

08003

IMIM (Hospital del Mar Medical Research Institute), Barcelona

All Listed Sponsors
lead

Parc de Salut Mar

OTHER

NCT04757532 - Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers. | Biotech Hunter | Biotech Hunter